{"id":"NCT01571453","sponsor":"H. Lundbeck A/S","briefTitle":"Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries","officialTitle":"Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2013-10","completion":null,"firstPosted":"2012-04-05","resultsPosted":"2014-10-13","lastUpdate":"2014-10-13"},"enrollment":437,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine (Lu AA21004)","otherNames":["Brintellix"]},{"type":"DRUG","name":"Venlafaxine extended release","otherNames":["EfexorÂ® XL"]}],"arms":[{"label":"Vortioxetine (Lu AA21004)","type":"EXPERIMENTAL"},{"label":"Venlafaxine extended release","type":"ACTIVE_COMPARATOR"}],"summary":"This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).","primaryOutcome":{"measure":"Change From Baseline in MADRS Total Score at Week 8","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"Vortioxetine","deltaMin":-19.36,"sd":0.7},{"arm":"Venlafaxine","deltaMin":-18.16,"sd":0.68}],"pValues":[{"comp":"OG000 vs OG001","p":"0.199"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["31990207","25650503"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":211},"commonTop":["Nausea","Dizziness","Dry mouth","Decreased appetite","Headache"]}}